UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction (IRS Employer Identification No.) 1900 Lake Park Drive, Suite 380 Smyrna, Georgia 30080 (Address of principal executive of ices) (Zip Code) (678) 384-7220 (Registrant's ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Gabrielle DeGravina – Investor Relations-CG Capital David Dodd – Chairman and Chief Executive Officer Mark Reynolds – Chief Financial Officer Kelly McKee – Chief Medical Officer John Sharkey – Vice President-Business Development Mark Newman – Chief Scientific Officer Conference Call Participants Robert LeBoyer – Noble Capital Markets Kumar Raja – ROTH Capital Jeffrey Kraws – Crystal Research Assoc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) 1900 Lake Park Drive, Suite 380 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 1900 Lake Park Drive, Suite 380 ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Gabrielle DeGravina - CG Capital David Dodd - Chairman, President and Chief Executive Officer Mark Reynolds - Chief Financial Officer Mark Newman - Chief Scientific Officer John Sharkey - Head, Business Development Kelly McKee - Chief Medical Officer Conference Call Participants Jeffrey Kraws - Crystal Research Associates Robert LeBoyer - Noble Capital Operator Good afternoon and welcome everyon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) 1900 Lake Park Driv ...

GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2022 Earnings Conference Call August 1, 2022 4:30 PM ET Company Participants David Dodd – Chairman and Chief Executive Officer Mark Reynolds – Chief Financial Officer Mark Newman – Chief Scientific Officer John Sharkey – Head, Business Development Conference Call Participants Jason McCarthy - Maxim Group Jeff Kraws - Crystal Research Kumarguru Raja - Brookline Capital Markets Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2022 Corporate Update Ca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-39563 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) Delaware 8 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 GEOVAX LABS, INC. (Exact name of registrant as specified in its charter) of incorporation or organization) Delaware 87-0455038 (State or other jurisdiction (IRS Employer Identification No.) 1900 Lake Pa ...